Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Selinexor and Venetoclax in Combination with Chemotherapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

Multiple Cancer Types

This phase I trial evaluates the side effects and best dose of selinexor and venetoclax in combination with chemotherapy in treating patients with acute myeloid leukemia or acute leukemia of ambiguous linage that has come back (relapsed) or does not respond to treatment. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Selinexor may stop the growth of cancer cells by blocking CRM1, which help the body's immune system to find and kill cancer cells. Chemotherapy drugs, such as fludarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Colony-stimulating factors, such as granulocyte colony-stimulating factor, may increase the production of blood cells and may help the immune system recover from the side effects of chemotherapy. Giving venetoclax and selinexor with chemotherapy may help control the disease in patients with acute myeloid leukemia or acute leukemia of ambiguous lineage.
Leukemia, Pediatric Leukemia, Pediatrics, Phase I
Zarnegar-Lumley, Sara

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

Multiple Cancer Types

This is a global, Phase 1/3, multicenter, open-label study to evaluate the efficacy and
safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-nave myelofibrosis
(MF) participants. The study will be conducted in two phases: Phase 1 and Phase 3. Phase 1
(enrollment completed) was an open-label evaluation of the safety and recommended dose (RD)
of selinexor in combination with ruxolitinib and included a dose escalation using a standard
3+3 design (Phase 1a) and a dose expansion part (Phase 1b). In Phase 3, JAKi treatment-nave
MF participants are enrolled in 2:1 ratio to receive the combination therapy of selinexor +
ruxolitinib or the combination of placebo + ruxolitinib.
Hematologic, Phase I
Mohan, Sanjay

To learn more about any of our clinical
trials, call 615-936-8422.